Because the phosphorylation of Akt (Ser473) was more strongly inhibited by the CCR4 antagonist than by the CCR2 antagonist, CCR4 may contribute more to prostate cancer cell migration than CCR2 (Figure 6B). This evidence concerns the gene AKT1 and prostate cancer.